An abundance of experimental data show that inflammation contributes to cerebral 
ischaemic injury and that attenuation of the inflammatory response can improve 
outcome. The two clinical trials of therapy aimed at limiting the inflammatory 
response in acute stroke that have been carried out to date, however, have not 
shown a benefit to such therapy. The potential reasons for the failure of these 
trials are discussed.